Pharmaceuticals

Global Opdivo (nivolumab) Market Forecast 2026–2035: Long-Term Growth Insights

March 8, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the opdivo (nivolumab) market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Opdivo (nivolumab) Market be in 2030 compared with 2026?

The market size for opdivo (nivolumab) has experienced significant expansion in recent years. This market is set to increase from $8.34 million in 2025 to $9.01 million in 2026, registering a compound annual growth rate (CAGR) of 8.1%. The historical growth of this market can be ascribed to several factors including the approval of PD-1 inhibitors, the escalating global burden of cancer, the inherent limitations of chemotherapy, favorable clinical trial outcomes, and the increasing adoption of immunotherapy by oncologists.

The market for Opdivo (nivolumab) is projected to experience robust expansion over the coming years. Its valuation is forecast to reach $12.13 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the projection period stems from several factors, including the broadening of its application into additional oncology areas, the development of more combination therapy approaches, enhanced patient selection through biomarkers, an uptick in cancer diagnoses, and elevated expenditures in oncology healthcare. Significant trends anticipated for this timeframe encompass the wider application of immune checkpoint inhibitors, a greater embrace of combination immunotherapy regimens, an increase in PD-1 based cancer treatments, expanded deployment across various cancer types, and a concentrated effort on achieving superior long-term survival results.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19914&type=smp

What Drivers Are Guiding Growth Patterns In The Opdivo (nivolumab) Market?

The rising occurrence of non-small lung cancer is projected to stimulate the expansion of the opdivo (nivolumab) market in the future. Non-small cell lung cancer (NSCLC) constitutes the predominant form of lung cancer, representing roughly 85% of all lung cancer diagnoses. This escalating prevalence of non-small cell lung cancer (NSCLC) is mainly linked to elements such as tobacco use, contact with environmental contaminants, genetic alterations, and a hereditary predisposition to cancer. Opdivo operates by inhibiting the PD-1 receptor found on immune cells, consequently boosting the body’s immunological capacity to identify and combat malignant cells. Illustratively, in 2024, the American Cancer Society, a US-based health entity, reported 234,580 new lung cancer cases in the US, of which 80% were non-small cell lung cancer (NSCLC). This figure indicates an increase compared to 2023, when 238,340 individuals were diagnosed with lung cancer. Therefore, the growing incidence of non-small lung cancer is propelling the growth of the opdivo (nivolumab) market.

How Is The Opdivo (nivolumab) Market Divided Into Segments?

The opdivo (nivolumab) market covered in this report is segmented –

1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL

2) By Dosage: Injection, Solution, Other Dosages

3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications

4) By End-User: Hospitals, Clinics, Other End Users

How Are New Market Trends Shaping The Landscape Of The Opdivo (nivolumab) Market?

Companies at the forefront of the Opdivo (nivolumab) market are prioritizing the development of advanced combination therapies. This focus aims to elevate treatment effectiveness, overcome mechanisms of resistance, and broaden the drug’s applicability across numerous cancer types. Combination therapy entails the deliberate use of Opdivo (nivolumab) alongside other agents, such as chemotherapy, to offer a more comprehensive therapeutic approach for individuals with advanced cancer. A notable example occurred in October 2024, when the Food and Drug Administration, a federal agency based in the US, granted approval for Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment, followed by single-agent nivolumab as adjuvant therapy after surgery, for adults presenting with resectable non-small cell lung cancer who do not possess known EGFR or ALK mutations. This crucial approval permits Opdivo to be utilized both before and after surgical intervention, enhancing therapeutic results for eligible patients.

Which Major Industry Participants Are Leading The Opdivo (nivolumab) Market Growth?

Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/opdivo-nivolumab-global-market-report-

Which Region Is Expected To Experience The Fastest Growth In The Opdivo (nivolumab) Market?

North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Opdivo (nivolumab) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19914&type=smp

Browse Through More Reports Similar to the Global Opdivo (nivolumab) Market 2026, By The Business Research Company

Nivolumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795